There are 2137 resources available
1395P - Who will maintain as long-term responders more than 3 years with first- or second-generation EGFR TKI among EGFR mutant NSCLC?
Presenter: Ja Hyun Yeo
Session: E-Poster Display
Resources:
Abstract
1396P - Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM cohort: The ELY study
Presenter: Pascaline Boudou Rouquette
Session: E-Poster Display
Resources:
Abstract
1397P - High incidence of treatment-related adverse events after combination EGFR tyrosine-kinase inhibitor and immune checkpoint inhibitors in EGFR-mutated metastatic non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Wai Ka Daisy Chan
Session: E-Poster Display
Resources:
Abstract
1398P - Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)
Presenter: Alessandro Dal Maso
Session: E-Poster Display
Resources:
Abstract
1399P - Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
Presenter: Janakiraman Subramanian
Session: E-Poster Display
Resources:
Abstract
1400P - Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
Presenter: Myung-Ju Ahn
Session: E-Poster Display
Resources:
Abstract
1401P - Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
Presenter: David Planchard
Session: E-Poster Display
Resources:
Abstract
1402P - Epidermal growth factor receptor mutation (EGFRm) testing in advanced non-small cell lung cancer (aNSCLC) in a real-world setting
Presenter: Janakiraman Subramanian
Session: E-Poster Display
Resources:
Abstract
1403P - EGFR-mutation testing and TKI treatment patterns in locally advanced or metastatic NSCLC in Norway: A nationwide cohort study
Presenter: Åslaug Helland
Session: E-Poster Display
Resources:
Abstract
1404P - Immune microenvironment could be responsible for response to immune checkpoint inhibitors among NSCLC patients with various EGFR mutation types
Presenter: Bo Yang
Session: E-Poster Display
Resources:
Abstract